Semler Scientific Inc
NASDAQ:SMLR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.03
66.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Semler Scientific Inc
Semler Scientific Inc
Cash & Cash Equivalents
Semler Scientific Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Semler Scientific Inc
NASDAQ:SMLR
|
Cash & Cash Equivalents
$6.6m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Semler Scientific Inc
Glance View
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Santa Clara, California and currently employs 124 full-time employees. The company went IPO on 2014-02-27. The firm develops, manufactures, and markets products and services that assist its customers in evaluating and treating chronic diseases. Its vascular testing product, QuantaFlo, measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (PAD). QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patient's vascular condition, including assessments of patients who have vascular disease. The company also has a distribution arrangement for the United States, including Puerto Rico, to distribute Insulin Insights, a software solution designed to provide insulin dosing recommendations to clinicians for the adjustment and maintenance of blood. The firm's customers for QuantaFlo include insurance plans, physician groups, and risk assessment groups.
See Also
What is Semler Scientific Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.6m
USD
Based on the financial report for Sep 30, 2024, Semler Scientific Inc's Cash & Cash Equivalents amounts to 6.6m USD.
What is Semler Scientific Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
1%
Over the last year, the Cash & Cash Equivalents growth was -82%. The average annual Cash & Cash Equivalents growth rates for Semler Scientific Inc have been -43% over the past three years , -5% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
